Aldeyra Therapeutics Inc. (ALDX)

7.40
0.20 2.80
NASDAQ : Health Technology
Prev Close 7.20
Open 7.14
Day Low/High 7.10 / 7.40
52 Wk Low/High 3.80 / 11.90
Volume 63.26K
Avg Volume 87.20K
Exchange NASDAQ
Shares Outstanding 19.66M
Market Cap 137.65M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data To The American Uveitis Society Held At The American Academy Of Ophthalmology 2017 Annual Meeting

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data To The American Uveitis Society Held At The American Academy Of Ophthalmology 2017 Annual Meeting

New Analyses Demonstrate Statistical Non-Inferiority of 0.5% Reproxalap Ophthalmic Solution to Corticosteroid

2 Small Biopharmas With Case of 'Hiccups'

2 Small Biopharmas With Case of 'Hiccups'

Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept Pharmaceuticals.

Aldeyra Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference

Aldeyra Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference

Presentation to Include Additional Data From Aldeyra's Recently Completed Phase IIa Clinical Trial of NS2 in Allergic Conjunctivitis

Analysts' Actions -- Check Point Software, ConAgra, Dillard's and More

Analysts' Actions -- Check Point Software, ConAgra, Dillard's and More

Here are Wednesday's top research calls, including an upgrade of ConAgra and new coverage of Dillard's.